Estramustine phosphate sodium

• CAT Number: I003898
• CAS Number: 52205-73-9
• Molecular Formula: C23H30Cl2NNa2O6P
• Molecular Weight: 564.35
• Purity: ≥95%
• Target: Cytoskeleton
• Solubility: 10 mM in H2O, DMSO: ＜ 7.8 mg/mL
• Storage: Inert atmosphere,2-8°C
• IUPAC Name: disodium;[(8R,9S,13S,14S,17S)-3-[bis(2-chloroethyl)carbamoyloxy]-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] phosphate
• InChI: InChI=1S/C23H32Cl2NO6P.2Na/c1-23-9-8-18-17-5-3-16(31-22(27)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)32-33(28,29)30;;/h3,5,14,18-21H,2,4,6-13H2,1H3,(H2,28,29,30);;/q;2*+1/p-2/t18-,19-,20+,21+,23+;;/m1../s1
• InChIKey: IIUMCNJTGSMNRO-VVSKJQCTSA-L
• SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OP(=O)([O-])[O-])CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl.[Na+].[Na+]

Estramustine Phosphate Sodium（Cat No.:I003898）is a chemotherapy drug combining the properties of an alkylating agent and an estrogen derivative. It is primarily used in the treatment of hormone-sensitive prostate cancer. The drug works by disrupting microtubule formation, inhibiting cell division, and inducing apoptosis in rapidly proliferating cancer cells. Its estrogenic component also suppresses testosterone levels, further inhibiting tumor growth. Estramustine Phosphate Sodium is typically used in combination with other anticancer agents to enhance therapeutic efficacy, making it a valuable option in prostate cancer treatment regimens.

Reference

[1]. Perry CM, et al. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging. 1995 Jul;7(1):49-74.
[2]. Bergenheim AT, et al. Pharmacokinetics and pharmacodynamics of estramustine phosphate. Clin Pharmacokinet. 1998 Feb;34(2):163-72.
[3]. Dene Simpson, et al. Estramustine Phosphate Sodium. American Journal of Cancer 2 (5): 373–390.